(Albany, US) DelveInsight has launched a new report on “Wilms Tumor Market Insights, Epidemiology, and Market Forecast-2030”
DelveInsight’s “Wilms Tumor Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Wilms Tumor, historical and forecasted epidemiology as well as the Wilms Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the Wilms Tumor facts:
Get more comprehensive insights into how Wilms Tumor epidemiological trends are impacting current and forecasted Wilms Tumor market @ Wilms Tumor Epidemiology Analysis and Forecast
Report key Highlights:
Nephroblastoma also is known as Wilms’ tumor is an embryonal type of renal cancer, is one of the most common solid malignant neoplasms in children. It accounts for approximately 90% of all pediatric tumors of the kidney. The total number of new cases of Wilms’ tumor in the UK is estimated at 80 cases per year. The tumor usually arises in a single kidney. Synchronous bilateral or multifocal tumors occur in approximately 10% of patients and tend to present at an earlier age. Wilms’ tumor can also be diagnosed in adolescents or adults, but this is extremely rare, representing less than 1% of all renal tumors.
WT arises from nephrogenic rests, which are undifferentiated embryonic tissues retained after birth. At the molecular level, in a proportion of patients, WT is the result of aberrations in the WT1 gene, located on chromosome 11p13. In addition to being a risk factor for WT, germline WT1 aberrations can cause renal and extra-renal developmental abnormalities and predispose to other malignancies. In the past two decades, there has been a considerable improvement in our understanding of WT and WT1.
Within Wilms’ tumors there are three main types of tumor cells; blastema, resembling the undifferentiated embryonic metanephric mesenchyme, and thought to contain any tumor stem cells, together with epithelium, and stroma, both thought to have differentiated from the blastema. These cell types are distinguished histologically and currently, there are no good markers to specifically identify blastema. All three elements arenot required, however, to have a diagnosis of Wilms tumor.
Request for Sample Copy: https://www.delveinsight.com/sample-request/wilms-tumor-market
Some of the Wilms Tumor companies:
Wilms Tumor Drugs Covered:
Table of Contents:
1. Key Insights
2. Executive Summary of Wilms Tumor
3. Competitive Intelligence Analysis for Wilms Tumor
4. Wilms Tumor: Market Overview at a Glance
5. Wilms Tumor: Disease Background and Overview
6. Patient Journey
7. Wilms Tumor Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Wilms Tumor Treatment
11. Marketed Products
12. Emerging Therapies
13. Wilms Tumor: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Wilms Tumor
17. KOL Views
18. Wilms Tumor Market Drivers
19. Wilms Tumor Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/wilms-tumor-market